Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 ...
MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") recently announced a ser ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results